Videos

“It's exciting to see that we now have another offering to men with enlarged prostates that has good outcomes and good durability up to 5 years [based on] the trials,” Kevin C. Zorn, MD, FRCSC, FACS.

Jaideep S. Sohi, MD, discusses the challenges with the use of conventional imaging in prostate cancer and how PSMA-PET alleviates these issues.

"I think it's about engaging with primary care. Primary care physicians need us to provide them with good education and good back-up," says Caroline Dowling, MBBS, MS, FRACS (Urol).

A comprehensive discussion on diagnostic practices in prostate cancer, highlighting imaging practices and the differences between castration-resistant prostate cancer and hormone-sensitive prostate cancer.

Matthew Smith, MD, PhD, and Brian T. Helfand, MD, introduce themselves and provide clinical insights on screening practices for patients with prostate cancer.

“Currently, in the area of tibial nerve stimulation, there are only 2 FDA approved options,” says Suzette E. Sutherland, MD, MS, FPMRS.

"I think it's important that they go visit someone that does them. Go to the operating room, see it in person," says Matthew E. Sterling, MD.

“These are the technologies that we'll see to empower patients and get more information, so that when we see the patient, it's one less thing we as a physician have to gather during that consultation, making the consultation more efficient,” says Kevin C. Zorn, MD, FRCSC, FACS.

"We're very much looking forward to being able to clinically implement these algorithms, both on the OAB side and the antibiotic resistance side," says Glenn T. Werneburg, MD, PhD.

Panelists discuss the importance of patient-centric approaches in the procedural treatment of overactive bladder (OAB). They share their practices in preparing patients for procedures, including patient education, shared decision-making, and tailoring pre-procedure instructions, with a focus on managing patient expectations and addressing fears. The episode emphasizes the role of the clinical team in ensuring patient comfort, highlighting practical considerations, real-world experiences, and best practices for optimizing patient-centered care in OAB management.

Experts share their long-term clinical experiences with intravesical botulinum toxin type A therapy, particularly emphasizing quality of life, patient satisfaction, simplicity, safety, and the comfort patients find in its non-permanent nature.

Experts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.

"We definitely need women to be able to access care quickly and efficiently. But, putting antibiotics at the forefront is not going to be the answer," says Caroline Dowling, MBBS, MS, FRACS (Urol).

"The happier you are in your personal life, I think, the better you are as a doctor, and the better you are as a doctor, the better you can be in your personal life," says Anne M. Suskind, MD, MS, FACS, FPMRS.

"There's fear that telehealth is going to be abused and overused, and the evidence doesn't necessarily point to that, but because of that fear, it does hold things back," says Chad Ellimoottil, MD, MS.

"Talking about the variety that's out there, the lack of regulation, and having things that are independently verified by labs can also enhance the patient outcome," says Bilal Chughtai, MD.

"There are patients who are not able to be submitted to an MRI due to metallic artifacts or to some conditions that are not compatible with the performance of an MRI," says Leonardo Kayat Bittencourt, MD, PhD.

"We're really enthusiastic on the overactive bladder end and on the antibiotic resistance end, but much more broadly, [AI is] set up to help us counsel our patients better and help us to improve outcomes for our patients as well," says Glenn T. Werneburg, MD, PhD.

"This a fantastic meeting that I really look forward to," says Nazih Paul Khater, MD, FACS.

"In fact, on multivariate analysis, they wanted to look at other health concerns that raise people's risk of getting kidney stones and the 3 things that came up from the study where the history of gallstones, hypertension, and chronic kidney disease," says Ben H. Chew, MD, MSc, FRCSC.

"Some of it actually is self-selecting because people are hearing about it more and come in asking about it first," says Brian Friel, MD.

In this insightful episode, Dr. Kennelly engages with Dr. Eilber and Dr. Benson in a comprehensive discussion of sacral neuromodulation and transcutaneous and posterior tibial nerve stimulation therapies used in the treatment of OAB, including their mechanisms, patient reception of FDA-approved devices, overall evolution and current practices implementation in clinical settings.

Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber share their experiences in the use of intravesical botulinum toxin type A as a treatment option for overactive bladder (OAB) into treatment plans. They provide insight into identifying optimal candidates, the outcomes they have observed, and benefits and risks, including strategies for managing these risks. They explore the decision-making process in guiding patients through various treatment options, considering individual lifestyles and preferences.

Drs Helfand, Chapin, and Collins, review the case of 67-year-old man treated with recurring prostate cancer.

Clinical oncologists present the case of a 62-year-old man with recurrent prostate cancer.

“One of those gigs was the New York section of the AUA, we did a fundraising event, which was a battle of the bands with 2 other urology departments that had bands as well,” says Debra Fromer, MD.

"I don't think 1 database study creates dogma, but I do think we can share these data with our patients and talk to them about treatment options and risk, have that difficult conversation about how BMI may be associated with that risk," says Cassandra K. Kisby, MD, MS.

"If payments are cut, our overall cost per visit goes up, which could be another disincentive to use virtual care," says Chad Ellimoottil, MD, MS.

“Our conclusion was that the amount of pattern 3 in men with grade groups 2, 3, and 4 is not predictive of oncologic outcome once you know the amount of 4,” says Andrew J. Vickers, PhD.